CN100335074C - 一种治疗中风病的中药口服液 - Google Patents
一种治疗中风病的中药口服液 Download PDFInfo
- Publication number
- CN100335074C CN100335074C CNB2005100126320A CN200510012632A CN100335074C CN 100335074 C CN100335074 C CN 100335074C CN B2005100126320 A CNB2005100126320 A CN B2005100126320A CN 200510012632 A CN200510012632 A CN 200510012632A CN 100335074 C CN100335074 C CN 100335074C
- Authority
- CN
- China
- Prior art keywords
- liquid
- oral liquid
- present
- chinese medicine
- apoplexy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 50
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 35
- 208000006011 Stroke Diseases 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000654 additive Substances 0.000 claims abstract description 4
- 241000237903 Hirudo Species 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 11
- 206010008118 cerebral infarction Diseases 0.000 abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 6
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 210000002385 vertebral artery Anatomy 0.000 abstract description 3
- 230000015271 coagulation Effects 0.000 abstract description 2
- 238000005345 coagulation Methods 0.000 abstract description 2
- 241000545744 Hirudinea Species 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 206010019468 Hemiplegia Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 208000000059 Dyspnea Diseases 0.000 description 7
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000013220 shortness of breath Diseases 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 6
- 230000003387 muscular Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 208000027219 Deficiency disease Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000024658 Epilepsy syndrome Diseases 0.000 description 2
- 208000002877 Epileptic Syndromes Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010019452 Hemianopia Diseases 0.000 description 1
- 208000007460 Hemianopsia Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 208000003773 Meningism Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241001125929 Trisopterus luscus Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000035581 baroreflex Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008087 cerebral arteritis Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000023158 meningismus Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
总例数 | 男 | 女 | 男∶女 | |
治疗组 | 60 | 50 | 10 | 5∶1 |
对照组 | 30 | 22 | 8 | 2.75∶1 |
合计 | 90 | 72 | 18 | 4∶1 |
总例数 | <40 | 40~50~60~70 | |||
治疗组 | 60 | 8 | 25 | 27 | |
对照组 | 30 | 1 | 13 | 16 | |
合计 | 90 | 9 | 38 | 43 |
总例数 | <24(h) | 2~3天 | 4~7天 | 7~14天 | |
治疗组对照组合计 | 603090 | 15823 | 12426 | 11415 | 221436 |
主症 次症 | ||||||||||||||
气短乏力 | 半身不遂 | 口舌歪斜 | 语不言蹇涩语 | 偏身麻木 | 口角流涎 | 自汗 | 心悸 | 手足肿胀 | 舌质暗淡 | 舌苔薄白 | 脉沉细 | 脉细缓 | 脉弦细 |
治疗组对照组合计 | 603090 | 171027 | 161026 | 252045 | 603090 | 281341 | 412162 | 412162 | 321951 | 391958 | 572582 | 241539 | 13518 | 21728 |
气短乏力 | 正常 | 日常体力劳动气短力弱 | 稍劳或行走气短乏力 | 室内缓行气短乏力 | 呼吸浅表或急促气力不足以息 |
语言表达 | 正常 | 一般表达基本正常 | 说话成句、而表达不全 | 只能说单词、词组 | 语言不能或基本不能 |
肢体麻木感觉异常 | 正常 | 肌肤发凉、肤色萎黄或偏白不华 | 痛、温、触感觉减退或异常 | 肢体麻木 | 痛、温、触感觉消失 |
上肢指关节肌力 | 正常 | 手指个别动作有效而肌力差 | 握拳伸指 | 指握不成拳不会伸 | 不会动 |
上肢肩关节肌力 | 正常 | 上举全而肌力差 | 上举平肩或略过肩 | 上举不到肩 | 不能动或前后略摆动 |
下肢髋关节肌力 | 正常 | 抬腿45度以上力弱 | 腿抬离床不足45度 | 摆动能平移 | 不能动 |
下肢趾关节肌力 | 正常 | 伸屈自如、力弱 | 伸屈不全、痛温触感觉减退 | 略动 | 不会动 |
综合功能 | 生活能自理、自由交谈 | 独立生活、简单劳动而有部分功能不全 | 可行走,部分自理,尚须人辅助 | 可站立迈步,需人随时照料 | 卧床 |
口眼歪斜(面瘫,水平凝视功能) | 正常 | 努嘴闭眼方见面瘫,目光呆滞 | 略瘫,可动,侧视动作欠灵敏 | 瘫痪不动侧视动作受限 | 面全瘫,眼球侧凝视 |
总例数(%) | 临床治愈(%) | 显效(%) | 有效(%) | 无效(%) | |
治疗组对照组 | 6030 | 3 5%1 3% | 27 45%12 40% | 24 40%9 30% | 6 10%8 26.66% |
合计 | 90 | 4 4.44% | 39 43.33% | 33 36.66% | 14.15. 56% |
主症 次症及舌脉象 | |||||||||||||
气短乏力 | 半身不遂 | 口舌歪斜 | 语 及言 不蹇 语涩 | 偏身麻木 | 口角流涎 | 自汗 | 心悸 | 手足肿胀 | 舌质暗淡 | 脉沉细 | 脉细缓 | 脉弦细 | |
治疗前治疗后组消失率(%)对疗前照疗后组消失率(%) | 593540.67291513.8 | 171417.6410100 | 1566010100 | 251540251924 | 393644.0629269.67 | 28273.5713930.77 | 41387.3121204.76 | 41387.3121207.76 | 322618.75191615.79 | 39234.02191426.32 | 24234.16151313.33 | 5420 | 21199.52770 |
P值 <0.05<0.05<0.05<0.05<0.05<0.05<0.05<0.05<0.05<0.05<0.05 |
总例数 | <40 | 40~50~60~70 |
临床治愈显效有效无效 | 327246 | 2222 | 18122 | 17104 |
总例数 | ≤1天 | 2~3天 | 4~7天 | 8~14天 | |
临床治愈显效有效无效 | 327246 | 1680 | 0642 | 2540 | 01084 |
例数 | X±SD(天) | T | P | |
治疗组对照组 | 31 | 1921 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100126320A CN100335074C (zh) | 2005-06-29 | 2005-06-29 | 一种治疗中风病的中药口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100126320A CN100335074C (zh) | 2005-06-29 | 2005-06-29 | 一种治疗中风病的中药口服液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1709318A CN1709318A (zh) | 2005-12-21 |
CN100335074C true CN100335074C (zh) | 2007-09-05 |
Family
ID=35705650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100126320A Expired - Fee Related CN100335074C (zh) | 2005-06-29 | 2005-06-29 | 一种治疗中风病的中药口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100335074C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101411742B (zh) * | 2008-11-18 | 2011-08-03 | 山西振东开元制药有限公司 | 芪蛭通络胶囊 |
CN101744867A (zh) * | 2008-12-08 | 2010-06-23 | 河北瑞生药业有限公司 | 一种治疗中风病的软胶囊及其制备方法 |
CN104771604B (zh) * | 2015-04-23 | 2018-05-18 | 贵阳中医学院 | 一种治疗中风的药物、制备方法及制剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095610A (zh) * | 1993-05-24 | 1994-11-30 | 潘世庆 | 治疗、预防妇科疾患的药物制剂妇病康 |
-
2005
- 2005-06-29 CN CNB2005100126320A patent/CN100335074C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095610A (zh) * | 1993-05-24 | 1994-11-30 | 潘世庆 | 治疗、预防妇科疾患的药物制剂妇病康 |
Non-Patent Citations (2)
Title |
---|
中药药剂学 范碧亭,154-156,上海科学技术出版社 2001 * |
黄芪、水蛭、地龙不同配伍治疗缺血性中风实验研究 翟晓翔,山东中医药大学学报,第24卷第1期 2000 * |
Also Published As
Publication number | Publication date |
---|---|
CN1709318A (zh) | 2005-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1709445A (zh) | 一种主治急慢性扭挫伤、风湿、类风湿疾病的藏药药物及其制备方法 | |
CN1742876A (zh) | 一种治疗跌打损伤的中药及其贴膏的制备工艺 | |
CN100335074C (zh) | 一种治疗中风病的中药口服液 | |
CN1709404A (zh) | 一种防治中风疾病的中成药及其生产方法、用途 | |
CN1245189C (zh) | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 | |
CN1772136A (zh) | 一种用于治疗筋腱软组织损伤及骨关节病的药物组合物及制备方法 | |
CN1660386A (zh) | 一种保健酒及制备方法 | |
CN1232267C (zh) | 用于治疗脑血管疾病的组合物及其制备方法和应用 | |
CN1289105C (zh) | 骨质消痛颗粒组合物及其制备方法 | |
CN1221280C (zh) | 一种治疗心脑血管疾病的中成药及其制备方法 | |
CN1723936A (zh) | 一种抗抑郁症的中药及其制备方法 | |
CN1718193A (zh) | 一种人参总次苷药物组合物及其制法和在制备治疗心肌缺血及失血性休克药物中的应用 | |
CN1663599A (zh) | 治疗风湿性、类风湿性疾病的狗皮膏(改进型)及其制备方法 | |
CN1284589C (zh) | 一种治疗急性脑血管疾病的药物及其制备方法 | |
CN1686485A (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1820770A (zh) | 一种治疗中风的中药组合物及其制备方法 | |
CN1290529C (zh) | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 | |
CN1060342C (zh) | 河豚鱼肝油在制备治疗药物依赖性的药物中的应用 | |
CN1526440A (zh) | 治疗肌肉萎缩肌无力-痿症的中药复方制剂及制备方法 | |
CN1810271A (zh) | 一种用于治疗中风的中药组合物及其制备方法和其用途 | |
CN1660207A (zh) | 降低血脂和胆固醇的保健制剂及其生产方法 | |
CN1615914A (zh) | 一种用于治疗中风病的药 | |
CN1650895A (zh) | 从天然植物复方制剂中提取增强记忆制品药物的方法 | |
CN1201795C (zh) | 一种治疗中风的药物及其生产方法 | |
CN1116880C (zh) | 河豚鱼肝油在制备治疗毒品依赖性的食品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
C56 | Change in the name or address of the patentee | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Hongzhi Inventor after: Wang Qifei Inventor after: Zhang Guosi Inventor before: Ma Hongzhi Inventor before: Wang Qifei Inventor before: Zhang Guosi |
|
CP01 | Change in the name or title of a patent holder |
Address after: 050035 Hebei city of Shijiazhuang province high tech Industrial Development Zone (East) Kunlun Street No. 85 Hebei Ruisheng Pharmaceutical Co. Ltd. Patentee after: Ma Hongzhi Address before: 050035 Hebei city of Shijiazhuang province high tech Industrial Development Zone (East) Kunlun Street No. 85 Hebei Ruisheng Pharmaceutical Co. Ltd. Patentee before: Ma Hongzhi |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20051221 Assignee: Hebei Ruisheng Pharmaceutical Co., Ltd. Assignor: Ma Hongzhi Contract record no.: 2014130000137 Denomination of invention: Chinese medicine oral liquid for treating apoplexia Granted publication date: 20070905 License type: Exclusive License Record date: 20140723 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070905 Termination date: 20180629 |
|
CF01 | Termination of patent right due to non-payment of annual fee |